Kyntra Bio Inc

KYNB

Healthcare Biotechnology

Kyntra Bio Inc’s revenue for fiscal 2025 (year ended December 2025) was $6.4 million, down 78.3% from fiscal 2024.

Revenue
n/m
EPS
n/m
Free cash flow
n/m

Quarter to June 2026, against a year earlier

3.11 0.33 −9.59%
Market cap
$13.0M
P/E
0.1×
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
5/9
ROIC
0.00%
Net debt / EBITDA
2.0×
Payout ratio
—

Where the cash went Q2 FY2026, quarter to 30 June 2026

Free cash flow was −$4.0M: capital expenditures were more than operating cash flow. Cash rose by $13.6M. What is a cash flow statement?

Free cash flow
−$4.0M
Returned to shareholders
$0.00
Debt, net
$0.00 borrowed
Change in cash
+$13.6M over the period
Where the cash went, in billions of dollars
Operating cash flow0.0
Free cash flow0.0
Acquisitions, net0.0
From investments, net0.0
Other0.0
Change in cash0.0

Figures in billions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.

Older periods Sep '25 Dec '25 Mar '26 Jun '26
Net Income

+8 more quarters

200.64 (14.22) (15.20) 11.97
Operating Cash Flow
(1.85) (18.33) (13.89) (3.99)
Investing cash flow
87.16 (51.71) 3.02 17.67
Financing cash flow
(85.92) (0.01) (0.01) 0.00
Ending Cash
(1.87) (70.10) 37.00 13.65

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 25 Oct 2026